LOGIN TO YOUR ACCOUNT

Username
Password
Remember Me
Or use your Academic/Social account:

CREATE AN ACCOUNT

Or use your Academic/Social account:

Congratulations!

You have just completed your registration at OpenAire.

Before you can login to the site, you will need to activate your account. An e-mail will be sent to you with the proper instructions.

Important!

Please note that this site is currently undergoing Beta testing.
Any new content you create is not guaranteed to be present to the final version of the site upon release.

Thank you for your patience,
OpenAire Dev Team.

Close This Message

CREATE AN ACCOUNT

Name:
Username:
Password:
Verify Password:
E-mail:
Verify E-mail:
*All Fields Are Required.
Please Verify You Are Human:
fbtwitterlinkedinvimeoflicker grey 14rssslideshare1
Devaney, Eileen; Gillan, Victoria (2016)
Publisher: Bentham Science Publishers Ltd.
Languages: English
Types: Article
Subjects:
Hsp90 inhibitors are well characterized in relation to their effects in a variety of tumors, with several inhibitors in various phases of clinical development. In recent years, the same inhibitor classes have been tested for efficacy in other systems, such as Alzheimer's disease and a variety of infectious disease models, including fungal and parasitic targets. In this article we discuss the repurposing of Hsp90 inhibitors for parasitic disease with a focus on parasitic nematode infections. We summarize the data that indicate that Hsp90 is functionally diverse in different nematode species and we discuss the challenges and prospects for developing these inhibitors as next generation chemotherapeutic tools.
  • The results below are discovered through our pilot algorithms. Let us know how we are doing!

    • 1. Taipale, M.; Jarosz, D. F.; Lindquist, S., HSP90 at the hub of protein homeostasis: emerging mechanistic insights. Nature reviews. Molecular cell biology 2010, 11 (7), 515-28.
    • 2. Echeverria, P. C.; Bernthaler, A.; Dupuis, P.; Mayer, B.; Picard, D., An interaction network predicted from public data as a discovery tool: application to the Hsp90 molecular chaperone machine. PloS one 2011, 6 (10), e26044.
    • 3. Neckers, L., Heat shock protein 90: the cancer chaperone. J Biosci 2007, 32 (3), 517-30.
    • 4. Burlison, J. A.; Avila, C.; Vielhauer, G.; Lubbers, D. J.; Holzbeierlein, J.; Blagg, B. S., Development of novobiocin analogues that manifest anti-proliferative activity against several cancer cell lines. The Journal of organic chemistry 2008, 73 (6), 2130-7.
    • 5. Taldone, T.; Ochiana, S. O.; Patel, P. D.; Chiosis, G., Selective targeting of the stress chaperome as a therapeutic strategy. Trends in pharmacological sciences 2014, 35 (11), 592-603.
    • 6. Neckers, L.; Trepel, J. B., Stressing the development of small molecules targeting HSP90. Clinical cancer research : an official journal of the American Association for Cancer Research 2014, 20 (2), 275-7.
    • 7. Pratt, W. B.; Gestwicki, J. E.; Osawa, Y.; Lieberman, A. P., Targeting hsp90/hsp70-based protein quality control for treatment of adult onset neurodegenerative diseases. Annual review of pharmacology and toxicology 2015, 55, 353-71.
    • 8. Kamal, A.; Thao, L.; Sensintaffar, J.; Zhang, L.; Boehm, M. F.; Fritz, L. C.; Burrows, F. J., A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature 2003, 425 (6956), 407-10.
    • 9. Moulick, K.; Ahn, J. H.; Zong, H.; Rodina, A.; Cerchietti, L.; Gomes DaGama, E. M.; Caldas-Lopes, E.; Beebe, K.; Perna, F.; Hatzi, K.; Vu, L. P.; Zhao, X.; Zatorska, D.; Taldone, T.; Smith-Jones, P.; Alpaugh, M.; Gross, S. S.; Pillarsetty, N.; Ku, T.; Lewis, J. S.; Larson, S. M.; Levine, R.; Erdjument-Bromage, H.; Guzman, M. L.; Nimer, S. D.; Melnick, A.; Neckers, L.; Chiosis, G., Affinity-based proteomics reveal cancer-specific networks coordinated by Hsp90. Nature chemical biology 2011, 7 (11), 818-26.
    • 10. Devaney, E., Thermoregulation in the life cycle of nematodes. International journal for parasitology 2006, 36 (6), 641-9.
    • 11. Figueras, M. J.; Echeverria, P. C.; Angel, S. O., Protozoan HSP90- heterocomplex: molecular interaction network and biological significance. Current protein & peptide science 2014, 15 (3), 245-55.
    • 12. Angel, S. O.; Figueras, M. J.; Alomar, M. L.; Echeverria, P. C.; Deng, B., Toxoplasma gondii Hsp90: potential roles in essential cellular processes of the parasite. Parasitology 2014, 141 (9), 1138-47.
    • 13. Wiesgigl, M.; Clos, J., Heat shock protein 90 homeostasis controls stage differentiation in Leishmania donovani. Molecular biology of the cell 2001, 12 (11), 3307-16.
    • 14. Hombach, A.; Clos, J., No stress--Hsp90 and signal transduction in Leishmania. Parasitology 2014, 141 (9), 1156-66.
    • 15. Pallavi, R.; Roy, N.; Nageshan, R. K.; Talukdar, P.; Pavithra, S. R.; Reddy, R.; Venketesh, S.; Kumar, R.; Gupta, A. K.; Singh, R. K.; Yadav, S. C.; Tatu, U., Heat shock protein 90 as a drug target against protozoan infections: biochemical characterization of HSP90 from Plasmodium falciparum and Trypanosoma evansi and evaluation of its inhibitor as a candidate drug. The Journal of biological chemistry 2010, 285 (49), 37964-75.
    • 16. Shahinas, D.; Folefoc, A.; Taldone, T.; Chiosis, G.; Crandall, I.; Pillai, D. R., A Purine Analog Synergizes with Chloroquine (CQ) by Targeting Plasmodium falciparum Hsp90 (PfHsp90). PloS one 2013, 8 (9), e75446.
    • 17. Wang, T.; Bisson, W. H.; Maser, P.; Scapozza, L.; Picard, D., Differences in conformational dynamics between Plasmodium falciparum and human Hsp90 orthologues enable the structure-based discovery of pathogen-selective inhibitors. Journal of medicinal chemistry 2014, 57 (6), 2524-35.
    • 18. Pizarro, J. C.; Hills, T.; Senisterra, G.; Wernimont, A. K.; Mackenzie, C.; Norcross, N. R.; Ferguson, M. A.; Wyatt, P. G.; Gilbert, I. H.; Hui, R., Exploring the Trypanosoma brucei Hsp83 potential as a target for structure guided drug design. PLoS neglected tropical diseases 2013, 7 (10), e2492.
    • 19. Johnson, K. S.; Wells, K.; Bock, J. V.; Nene, V.; Taylor, D. W.; Cordingley, J. S., The 86-kilodalton antigen from Schistosoma mansoni is a heat-shock protein homologous to yeast HSP-90. Molecular and biochemical parasitology 1989, 36 (1), 19-28.
    • 20. Greenberg, R. M., Schistosome ABC multidrug transporters: From pharmacology to physiology. International journal for parasitology. Drugs and drug resistance 2014, 4 (3), 301-9.
    • 21. Wenkert, D.; Ramirez, B.; Shen, Y.; Kron, M. A., In Vitro Activity of Geldanamycin Derivatives against Schistosoma japonicum and Brugia malayi. Journal of parasitology research 2010, 2010, 716498.
    • 22. Ittiprasert, W.; Knight, M., Reversing the resistance phenotype of the Biomphalaria glabrata snail host Schistosoma mansoni infection by temperature modulation. PLoS pathogens 2012, 8 (4), e1002677.
    • 23. Hotez, P. J.; Brindley, P. J.; Bethony, J. M.; King, C. H.; Pearce, E. J.; Jacobson, J., Helminth infections: the great neglected tropical diseases. The Journal of clinical investigation 2008, 118 (4), 1311-21.
    • 24. Menzies, S. K.; Rodriguez, A.; Chico, M.; Sandoval, C.; Broncano, N.; Guadalupe, I.; Cooper, P. J., Risk factors for soil-transmitted helminth infections during the first 3 years of life in the tropics; findings from a birth cohort. PLoS neglected tropical diseases 2014, 8 (2), e2718.
    • 25. Geary, T. G.; Woo, K.; McCarthy, J. S.; Mackenzie, C. D.; Horton, J.; Prichard, R. K.; de Silva, N. R.; Olliaro, P. L.; Lazdins-Helds, J. K.; Engels, D. A.; Bundy, D. A., Unresolved issues in anthelmintic pharmacology for helminthiases of humans. Int J Parasitol 2010, 40 (1), 1-13.
    • 26. Nutman, T. B., Insights into the pathogenesis of disease in human lymphatic filariasis. Lymphatic research and biology 2013, 11 (3), 144-8.
    • 27. Murdoch, M. E., Onchodermatitis. Current opinion in infectious diseases 2010, 23 (2), 124-31.
    • 28. Buxton, S. K.; Robertson, A. P.; Martin, R. J., Diethylcarbamazine increases activation of voltage-activated potassium (SLO-1) currents in Ascaris suum and potentiates effects of emodepside. PLoS neglected tropical diseases 2014, 8 (11), e3276.
    • 29. Subramanian, S.; Stolk, W. A.; Ramaiah, K. D.; Plaisier, A. P.; Krishnamoorthy, K.; Van Oortmarssen, G. J.; Dominic Amalraj, D.; Habbema, J. D.; Das, P. K., The dynamics of Wuchereria bancrofti infection: a model-based analysis of longitudinal data from Pondicherry, India. Parasitology 2004, 128 (Pt 5), 467-82.
    • 30. Hoerauf, A., Filariasis: new drugs and new opportunities for lymphatic filariasis and onchocerciasis. Current opinion in infectious diseases 2008, 21 (6), 673-81.
    • 31. Johnston, K. L.; Ford, L.; Umareddy, I.; Townson, S.; Specht, S.; Pfarr, K.; Hoerauf, A.; Altmeyer, R.; Taylor, M. J., Repurposing of approved drugs from the human pharmacopoeia to target Wolbachia endosymbionts of onchocerciasis and lymphatic filariasis. International journal for parasitology. Drugs and drug resistance 2014, 4 (3), 278-86.
    • 32. Gilleard, J. S., Haemonchus contortus as a paradigm and model to study anthelmintic drug resistance. Parasitology 2013, 140 (12), 1506-22.
    • 33. Nana-Djeunga, H.; Bourguinat, C.; Pion, S. D.; Kamgno, J.; Gardon, J.; Njiokou, F.; Boussinesq, M.; Prichard, R. K., Single nucleotide polymorphisms in beta-tubulin selected in Onchocerca volvulus following repeated ivermectin treatment: possible indication of resistance selection. Molecular and biochemical parasitology 2012, 185 (1), 10-8.
    • 34. Thompson, F. J.; Cockroft, A. C.; Wheatley, I.; Britton, C.; Devaney, E., Heat shock and developmental expression of hsp83 in the filarial nematode Brugia pahangi. European journal of biochemistry / FEBS 2001, 268 (22), 5808-15.
    • 35. Devaney, E.; O'Neill, K.; Harnett, W.; Whitesell, L.; Kinnaird, J. H., Hsp90 is essential in the filarial nematode Brugia pahangi. International journal for parasitology 2005, 35 (6), 627-36.
    • 36. Johnson, J. L.; Brown, C., Plasticity of the Hsp90 chaperone machine in divergent eukaryotic organisms. Cell Stress Chaperones 2009, 14 (1), 83-94.
    • 37. Lok, J. B., Nucleic acid transfection and transgenesis in parasitic nematodes. Parasitology 2012, 139 (5), 574-88.
    • 38. Selkirk, M. E.; Huang, S. C.; Knox, D. P.; Britton, C., The development of RNA interference (RNAi) in gastrointestinal nematodes. Parasitology 2012, 139 (5), 605-12.
    • 39. Britton, C.; Murray, L., Using Caenorhabditis elegans for functional analysis of genes of parasitic nematodes. Int J Parasitol 2006, 36 (6), 651-9.
    • 40. Glendinning, S. K.; Buckingham, S. D.; Sattelle, D. B.; Wonnacott, S.; Wolstenholme, A. J., Glutamate-gated chloride channels of Haemonchus contortus restore drug sensitivity to ivermectin resistant Caenorhabditis elegans. PloS one 2011, 6 (7), e22390.
    • 41. Birnby, D. A.; Link, E. M.; Vowels, J. J.; Tian, H.; Colacurcio, P. L.; Thomas, J. H., A transmembrane guanylyl cyclase (DAF-11) and Hsp90 (DAF-21) regulate a common set of chemosensory behaviors in caenorhabditis elegans. Genetics 2000, 155 (1), 85-104.
    • 42. David, C. L.; Smith, H. E.; Raynes, D. A.; Pulcini, E. J.; Whitesell, L., Expression of a unique drug-resistant Hsp90 ortholog by the nematode Caenorhabditis elegans. Cell Stress Chaperones 2003, 8 (1), 93-104.
    • 43. Taldone, T.; Gillan, V.; Sun, W.; Rodina, A.; Patel, P.; Maitland, K.; O'Neill, K.; Chiosis, G.; Devaney, E., Assay strategies for the discovery and validation of therapeutics targeting Brugia pahangi Hsp90. PLoS neglected tropical diseases 2010, 4 (6), e714.
    • 44. Gillan, V.; Maitland, K.; McCormack, G.; Him, N. A.; Devaney, E., Functional genomics of hsp-90 in parasitic and free-living nematodes. International journal for parasitology 2009, 39 (10), 1071-81.
    • 45. Winter, A. D.; McCormack, G.; Myllyharju, J.; Page, A. P., Prolyl 4- hydroxlase activity is essential for development and cuticle formation in the human infective parasitic nematode Brugia malayi. J Biol Chem 2013, 288 (3), 1750-61.
    • 46. Haslbeck, V.; Kaiser, C. J.; Richter, K., Hsp90 in non-mammalian metazoan model systems. Biochimica et biophysica acta 2012, 1823 (3), 712-21.
    • 47. Walton-Diaz, A.; Khan, S.; Bourboulia, D.; Trepel, J. B.; Neckers, L.; Mollapour, M., Contributions of co-chaperones and post-translational modifications towards Hsp90 drug sensitivity. Future medicinal chemistry 2013, 5 (9), 1059-71.
    • 48. Him, N. A.; Gillan, V.; Emes, R. D.; Maitland, K.; Devaney, E., Hsp-90 and the biology of nematodes. BMC evolutionary biology 2009, 9, 254.
    • 49. Gillan, V.; Devaney, E., Nematode Hsp90: highly conserved but functionally diverse. Parasitology 2014, 141 (9), 1203-15.
    • 50. Prodromou, C.; Nuttall, J. M.; Millson, S. H.; Roe, S. M.; Sim, T. S.; Tan, D.; Workman, P.; Pearl, L. H.; Piper, P. W., Structural basis of the radicicol resistance displayed by a fungal hsp90. ACS Chem Biol 2009, 4 (4), 289-97.
    • 51. McSorley, H. J.; Hewitson, J. P.; Maizels, R. M., Immunomodulation by helminth parasites: defining mechanisms and mediators. International journal for parasitology 2013, 43 (3-4), 301-10.
    • 52. Martin, R. J.; Robertson, A. P., Control of nematode parasites with agents acting on neuro-musculature systems: lessons for neuropeptide ligand discovery. Advances in experimental medicine and biology 2010, 692, 138-54.
    • 53. Foster, J. M.; Kumar, S.; Ganatra, M. B.; Kamal, I. H.; Ware, J.; Ingram, J.; Pope-Chappell, J.; Guiliano, D.; Whitton, C.; Daub, J.; Blaxter, M. L.; Slatko, B. E., Construction of bacterial artificial chromosome libraries from the parasitic nematode Brugia malayi and physical mapping of the genome of its Wolbachia endosymbiont. Int J Parasitol 2004, 34 (6), 733-46.
    • 54. Gillan, V.; O'Neill, K.; Maitland, K.; Sverdrup, F. M.; Devaney, E., A repurposing strategy for Hsp90 inhibitors demonstrates their potency against filarial nematodes. PLoS neglected tropical diseases 2014, 8 (2), e2699.
    • 55. Godel, C.; Kumar, S.; Koutsovoulos, G.; Ludin, P.; Nilsson, D.; Comandatore, F.; Wrobel, N.; Thompson, M.; Schmid, C. D.; Goto, S.; Bringaud, F.; Wolstenholme, A.; Bandi, C.; Epe, C.; Kaminsky, R.; Blaxter, M.; Maser, P., The genome of the heartworm, Dirofilaria immitis, reveals drug and vaccine targets. FASEB journal : official publication of the Federation of American Societies for Experimental Biology 2012, 26 (11), 4650-61.
    • 56. Bourguinat, C.; Keller, K.; Blagburn, B.; Schenker, R.; Geary, T. G.; Prichard, R. K., Correlation between loss of efficacy of macrocyclic lactone heartworm anthelmintics and P-glycoprotein genotype. Veterinary parasitology 2011, 176 (4), 374-81.
    • 57. Barrott, J. J.; Hughes, P. F.; Osada, T.; Yang, X. Y.; Hartman, Z. C.; Loiselle, D. R.; Spector, N. L.; Neckers, L.; Rajaram, N.; Hu, F.; Ramanujam, N.; Vaidyanathan, G.; Zalutsky, M. R.; Lyerly, H. K.; Haystead, T. A., Optical and radioiodinated tethered Hsp90 inhibitors reveal selective internalization of ectopic Hsp90 in malignant breast tumor cells. Chemistry & biology 2013, 20 (9), 1187-97.
    • 58. Cheeseman, I. H.; Miller, B. A.; Nair, S.; Nkhoma, S.; Tan, A.; Tan, J. C.; Al Saai, S.; Phyo, A. P.; Moo, C. L.; Lwin, K. M.; McGready, R.; Ashley, E.; Imwong, M.; Stepniewska, K.; Yi, P.; Dondorp, A. M.; Mayxay, M.; Newton, P. N.; White, N. J.; Nosten, F.; Ferdig, M. T.; Anderson, T. J., A major genome region underlying artemisinin resistance in malaria. Science 2012, 336 (6077), 79-82.
    • 59. Kaplan, R. M.; Vidyashankar, A. N., An inconvenient truth: global worming and anthelmintic resistance. Veterinary parasitology 2012, 186 (1-2), 70-8.
    • 60. Mitchell, S. N.; Stevenson, B. J.; Muller, P.; Wilding, C. S.; Egyir-Yawson, A.; Field, S. G.; Hemingway, J.; Paine, M. J.; Ranson, H.; Donnelly, M. J., Identification and validation of a gene causing cross-resistance between insecticide classes in
  • No similar publications.

Share - Bookmark

Funded by projects

Cite this article